Preoperative treatment with PAXG leads to a significantly longer event-free survival than that with modified FOLFIRINOX in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/paxg-vs-modified-folfirinox-resectable-pancreatic-cancer-2025a1000x9c?src=rss
Author :
Publish date : 2025-12-01 12:00:00
Copyright for syndicated content belongs to the linked Source.
